Aeolus Announces Second Quarter Fiscal Year 2016 Financial Results and Investor Update Call
May 16, 2016 08:00 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - May 16, 2016) -
Aeolus Pharmaceuticals, Inc.
(OTCQB: AOLS), a biotechnology company developing compounds to protect against fibrosis, inflammation,...
European Patent Issued and Patent Allowed in Japan for Aeolus' Parkinson's Disease Compound AEOL 11114
April 18, 2016 08:00 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA --(Marketwired - April 18, 2016) - Aeolus Pharmaceuticals (OTCQB: AOLS)
AEOL 11114 Is Subject of Michael J Fox Foundation Research Grant Program
...
Aeolus Announces Removal of FDA Clinical Hold on AEOL 10150; Initiation of Phase 1 Study in Healthy Volunteers Planned for 2nd Quarter 2016
February 22, 2016 08:00 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - February 22, 2016) - Aeolus Pharmaceuticals, Inc.(OTCQB: AOLS), a biotechnology company developing compounds to protect against fibrosis, inflammation, nerve...
Aeolus Announces First Quarter Fiscal Year 2016 Financial Results
February 16, 2016 17:08 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - February 16, 2016) -
Aeolus Pharmaceuticals, Inc.
(OTCQB: AOLS), a biotechnology company developing compounds to protect against fibrosis, inflammation,...
Aeolus Announces Fiscal Year 2015 Financial Results
December 18, 2015 17:09 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - December 18, 2015) -
Aeolus Pharmaceuticals, Inc.
(OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and...
Aeolus Announces $6.75 Million Private Placement Financing
December 15, 2015 15:22 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - December 15, 2015) -
Aeolus Pharmaceuticals, Inc.
(OTCQB: AOLS), a biotechnology company developing compounds to protect against fibrosis, inflammation,...
Aeolus Announces $6.75 Million Private Placement Financing
December 14, 2015 07:00 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - December 14, 2015) -
Aeolus Pharmaceuticals, Inc.
(OTCQB: AOLS), a biotechnology company developing compounds to protect against fibrosis, inflammation,...
Aeolus Announces Formation of Pulmonary Fibrosis Clinical Advisory Board
November 04, 2015 08:30 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - November 04, 2015) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against fibrosis, inflammation, nerve damage...
Aeolus Receives Notice of Patent Allowance for New Compound That Demonstrated Efficacy in Michael J. Fox Foundation Research Grant Program
November 02, 2015 08:30 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - November 02, 2015) - PRE-CLINICAL WORK UNDERWAY WITH IND FILING FOR PARKINSON'S DISEASE TARGETED IN 2017EFFICACY DEMONSTRATED IN TWO PARKINSON'S DISEASE MODELS...
Aeolus Announces Publication of Study Showing AEOL 10150 Improves Memory and Protects Brain Damage in an Animal Model of Epilepsy
August 18, 2015 08:00 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - August 18, 2015) - FINDINGS REPORTED BY DR. MANISHA PATELOF THE UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS, DEPARTMENT OF PHARMACEUTICAL SCIENCES AND PUBLISHED...